Transport characteristics of ginkgolide B by Caco-2 cells and examination of ginkgolide B oral absorption potential using rat in situ intestinal loop method

International Journal of Pharmaceutics

Volumn 351, Issue 1-2, 2008, Pages 31-35

  Lv, Hua ^a   Wang, Guangji ^a   Wu, Xiaolan ^a   Xie, Lin ^a   Huang, Chenrong ^a   Li, Hao ^a   Liang, Yan ^a   Hao, Haiping ^a   Sun, Jie ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Caco 2 cells; Ginkgolide B; In situ closed intestinal loop; Intestinal absorption

Indexed keywords

GINKGOLIDE B;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE LOOP; INTESTINE MUCOSA; MALE; MASS SPECTROMETRY; NONHUMAN; OXYGEN SATURATION; PH; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; GINKGO BILOBA; GINKGOLIDES; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINE, LARGE; INTESTINE, SMALL; LACTONES; MALE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38749133769     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.026     Document Type: Article

References (11)

1. Biber A., and Koch E. Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS. Planta Med. 65 (1999) 192-193
2. Ishii H., Dzvuba S.V., and Nakanishi K. Lactone-free ginkgolides via regioselective DIBAL-H reduction. Org. Biomol. Chem. 3 (2005) 3471-3472
3. Kanowski S., Hermann W.M., Stephan K., Wierich W., and Hoerr R. Proof of efficacy of the ginkgo biloba special extract Eginkgolide B 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29 (1996) 47-56
4. Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., and Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. J. Am. Med. Assoc. 278 (1997) 1327-1332
5. Liang-Shang L., Dhiren Gan., and Thakker R. Application of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv. Drug Deliv. Rev. 23 (1997) 77-98
6. Lv H., Wang G.J., Li H., Huang M.W., Xie H.T., Huang C.R., Sun J.G., and Lv T. Sensitive and selective liquid chromatography-electrospray ionization mass spectrometry analysis of ginkgolide B in dog plasma. J. Pharm. Biomed. Anal. 40 (2006) 88-94
7. Maclennan K.M., Darlington C.L., and Smith P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 67 (2002) 235-257
8. Mikihisa T., Yuka K., Hiromi N., Teruo M., and Ryoko Y. Segment-selective absorption of lysozyme in the intestine. Eur. J. Pharmacol. 502 (2004) 149-155
9. 18) in rats: regional difference in stability and hypocalcemic effect. Pharm. Dev. Technol. 10 (2005) 389-396
10. Sha X.Y., and Fang X.L. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. Int. J. Pharm. 272 (2004) 161-171
11. Van Beek T.A. Ginkgolides and bilobalide: their physical, chromatographic and spectroscopic properties. Bioorg. Med. Chem. 13 (2005) 5001-5012